BHARATI INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH & DEVELOPMENT (BIJMRD)

(Open Access Peer-Reviewed International Journal)

DOI Link :: https://doi.org/10.70798/Bijmrd/020900014

Available Online: www.bijmrd.com|BIJMRD Volume: 2| Issue: 9| October 2024| e-ISSN: 2584-1890

Optimizing Paediatric Tuberculosis Treatment: Efficacy and Safety of Immediate-Release Anti-Tubercular Formulations

Anirban Nandi

Ph.D. Research Scholar, Department of Pharmacy, SunRise University, Alwar, Rajasthan

E-mail -anirbanbcrcp@gmail.com

Abstract:

Tuberculosis (TB) in children remains a significant public health issue, especially in regions with high TB prevalence. Effective treatment options for paediatric patients are crucial to ensure rapid recovery, reduce disease transmission, and prevent drug resistance. This paper explores the efficacy and safety of immediate-release anti-tubercular formulations specifically designed for paediatric use. Immediate-release formulations allow the active drug ingredients to be released quickly in the body, leading to a faster therapeutic response. However, concerns exist regarding their safety and effectiveness in children, who have different pharmacological needs than adults. The study reviews current research and clinical data to evaluate the impact of these medications on treatment outcomes, side effects, and overall safety in children with TB. We aim to determine whether immediate-release formulations effectively achieve the desired therapeutic levels without causing harmful side effects. The findings highlight the potential of immediate-release anti-tubercular medications to improve treatment adherence and clinical outcomes in young patients. However, close monitoring and further research are recommended to ensure these formulations meet paediatric safety standards. This paper contributes to the development of optimal TB treatment protocols for children, aiming for faster recovery and better quality of life for paediatric TB patients.

Keywords: *Paediatric Tuberculosis, Immediate-Release Formulations, Anti-Tubercular Drugs, Paediatric Pharmacology, Tuberculosis Treatment, Drug Safety in Children, Clinical Efficacy.*

Introduction:

Tuberculosis (TB) remains one of the leading infectious diseases worldwide, affecting millions of people, especially in developing countries. While TB can affect anyone, children are particularly vulnerable due to their still-developing immune systems. Paediatric tuberculosis is a significant health challenge because children face unique risks, and their treatment requires special attention to dosage and formulation. Unlike adults, who can often tolerate a broader range of medications, children need medicines that are not only effective but also safe and suitable for their developing bodies. The World Health Organization (WHO) has stressed the importance of accessible, child-friendly TB treatments to address this urgent need. Immediate-release (IR) formulations of anti-tubercular drugs are widely used in paediatric treatment due to their rapid onset of action and ease of administration. These formulations release the medication quickly into the bloodstream, making them suitable for treating acute infections like TB. However, achieving the right

balance of efficacy and safety in these formulations can be challenging. Efficacy refers to how well the medication works to kill the TB bacteria and prevent further infection, while safety focuses on minimizing harmful side effects. Children are particularly sensitive to medication dosages, so there is a critical need to ensure that the drugs are safe for daily use over long periods.

In recent years, research has focused on optimizing paediatric anti-tubercular IR formulations to make them more effective and safer. Studies have looked at factors such as dosage adjustments, the combination of drugs, and the development of child-friendly formulations, such as dispersible tablets, which can be dissolved in water. Such advancements aim to improve treatment adherence, as children are more likely to complete their treatment if the medication is easy to take and has fewer side effects. This paper explores the current developments in immediate-release anti-tubercular formulations for children, examining both their efficacy in treating paediatric TB and their safety profile. The objective is to identify the best practices for using these formulations in paediatric care, aiming to improve treatment outcomes and reduce the burden of TB in children. By reviewing existing research, this paper also aims to highlight areas where further studies are needed, including long-term safety, potential side effects, and ways to increase access to these critical medications in low-resource settings. Ultimately, optimizing paediatric TB treatment will contribute significantly to controlling and eventually eliminating tuberculosis in vulnerable populations worldwide.

Literature Review:

Manem et al. (2022) examined the ocular safety of ethambutol in paediatric patients with drug-sensitive tuberculosis. Conducted from December 2018 to August 2020, the study evaluated 94 eyes from 47 children, assessing various visual parameters like acuity, visual fields, colour perception, and retinal nerve fibre layer thickness using optical coherence tomography. No adverse effects were found on visual acuity, colour vision, or other visual functions after treatment, supporting ethambutol's safety at a maximum dose of 20 mg/kg/day throughout therapy for children with TB. Matawo et al. (2020) addressed the global challenge of paediatric TB treatment, especially the scarcity of child-friendly formulations. This study developed a pyrazinamide-containing edible film using aqueous-blending and solvent-casting methods. This film formulation disintegrated rapidly within 60 seconds and showed promising stability, safety, and flexibility, making it a suitable candidate for young children, particularly those under five, by improving TB treatment accessibility and adherence. Tetali et al. (2020) highlighted the rising challenge of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains, emphasizing the need for new treatments with shorter, less toxic regimens. This study reviewed 23 emerging drug candidates undergoing clinical trials, evaluating their effectiveness and potential to combat resistant TB strains. Despite current WHO-approved treatments, less than half of drug-resistant cases achieve satisfactory outcomes, underscoring the demand for novel and more accessible medications.

Mukherjee et al. (2019) discussed the critical need for optimized dosing of first-line anti-TB drugs, such as isoniazid, rifampicin, pyrazinamide, and ethambutol, for paediatric patients. While dosage adjustments have improved drug exposure, achieving therapeutic levels still requires tailored dosing based on factors like age, nutritional status, and genetic differences. The study recommended extending adult trials on higher rifampicin doses to children, supporting a more individualized approach to optimize treatment. Hussain et al. (2019) explored advanced drug delivery methods to reduce the side effects and dosage-related toxicities in TB treatment. Highlighting drug resistance and patient compliance issues, the study advocated for targeted carriers to deliver anti-TB drugs directly to infection sites. These innovations in drug delivery systems, such as nano-carriers, could enhance therapeutic outcomes and patient compliance, particularly in cases of resistant TB strains. Additionally, potential new WHO-endorsed vaccines may offer preventive strategies soon. Athulnadh et al. (2020) examined childhood TB treatment challenges, noting significant societal impacts from high toxicity levels associated with the Directly Observed Treatment Short Course (DOTS). This toxicity, particularly in the intense phase of therapy, poses risks of hepatotoxicity, though side effects

tend to be milder in children. The study stressed the need for safer paediatric formulations to reduce these adverse outcomes. Motta et al. (2018) discussed WHO's 2035 TB eradication goal and the role of pharmacokinetic and pharmacogenetic research in improving treatment outcomes. The study emphasized Therapeutic Drug Monitoring and dose customization based on individual genetic profiles, such as NAT2 acetylation status and SLCO1B1 gene variations, to reduce drug resistance and optimize treatment success.

Wang et al. (2017) conducted a retrospective study on thalidomide's efficacy in children with drug-resistant TB who had failed other treatments. Given at a dose of 1.2-2.5 mg/kg daily, thalidomide achieved clinical remission in 60% of cases, showing potential as a safe alternative for paediatric TB patients in specific contexts. Parumasivam et al. (2016) focused on the potential of pulmonary delivery systems for TB treatment. They emphasized that delivering drugs directly to the lungs could reduce doses and side effects. Stable dry powder formulations for inhalers, suited for high-dose delivery, were highlighted as a promising non-invasive method to treat TB more effectively. Hoagland et al. (2016) examined the paediatric TB burden, noting socioeconomic barriers and difficulties in diagnosis among children. The study reviewed both current and emerging TB medications, evaluating their suitability for paediatric use, especially for resistant strains. Novel agents in development hold the potential to improve treatment for multidrug-resistant TB in children. Nandha et al. (2013) addressed co-infection concerns of TB with AIDS and introduced bedaquiline as a promising second-line drug for MDR-TB. Known for its sustained efficacy, shorter treatment duration, and reduced resistance risks, bedaquiline has been studied extensively for its safety and effectiveness, though primarily in adults, underscoring the need for similar studies in paediatric populations.

Significance of the Study:

Research on developing effective and safe anti-tubercular immediate-release formulations for children is essential, as paediatric tuberculosis (TB) remains a major global health issue, particularly in high-prevalence areas. Children are especially vulnerable to severe TB, making timely and appropriate treatment critical. However, limited paediatric-specific formulations often lead to dosing inaccuracies, treatment failures, and increased drug resistance. Improving access to paediatric-specific, immediate-release formulations would enhance treatment outcomes, ensuring children receive medications tailored to their physiological needs, thereby increasing efficacy and reducing side effects. Effective TB treatment in children also helps lower the overall disease burden by preventing transmission within communities.

This research aligns with global health goals, particularly Sustainable Development Goal 3, which promotes healthy lives and well-being for all ages. By focusing on paediatric TB, we address health disparities and contribute to equitable healthcare access, ultimately building a healthier future. Investing in these formulations not only meets immediate health needs but also has the potential to transform paediatric TB treatment worldwide, benefiting countless children.

Objectives of the Study:

Objective 1: To formulate immediate-release anti-tubercular medications specifically designed for paediatric use, considering age-appropriate dosages, palatability, and rapid drug release.

Objective 2: To assess the pharmacokinetics and pharmacodynamics of the newly formulated paediatric anti-tubercular immediate-release medications, ensuring optimal drug concentrations and therapeutic efficacy in paediatric patients.

Objective 3: To evaluate the safety and tolerability of the paediatric-specific immediate-release formulations through rigorous clinical trials, monitoring adverse effects, and ensuring appropriate management strategies for any identified side effects.

Research Methodology:

This study follows a structured, multidisciplinary approach to develop and evaluate paediatric anti-tubercular immediate-release formulations. Initially, a thorough literature review and pharmaceutical studies will inform the design of child-friendly medications, focusing on appropriate dosages, palatability, and rapid drug release. Following formulation, pharmacokinetic and pharmacodynamic assessments will be performed to ensure optimal therapeutic effectiveness for paediatric patients. Safety and tolerability will be rigorously evaluated through clinical trials, with adverse effects closely monitored and managed. Additionally, a socio-economic analysis will assess the broader impact of these formulations, including potential reductions in disease transmission, healthcare costs, and improved quality of life for children and their families. Integrating expertise from pharmaceutical sciences, paediatrics, microbiology, and public health, the study combines quantitative and qualitative methods—such as laboratory tests, clinical evaluations, and economic modelling—to provide insights into the development and impact of paediatric anti-tubercular formulations, aiming to advance treatment and health outcomes for children affected by tuberculosis.

Discussion:

This paper focuses on developing and optimizing anti-tubercular medications specifically designed for children. Tuberculosis (TB) is a serious infectious disease, and children are particularly vulnerable to its impacts. Treating TB in children requires a unique approach compared to adults, as children have different needs and responses to medication. This study aims to create an effective, safe, and easy-to-take anti-TB medication that is both age-appropriate and pleasant for young patients. The goal is to develop an "immediate-release" formulation—meaning that the drug is quickly absorbed in the body after being taken. For paediatric patients, immediate release is essential because it ensures a quick response to the medication, which is crucial in managing TB's progression. Age-appropriate dosages are also a core focus, as children's bodies process medications differently than adults; they need carefully measured amounts to avoid under dosing or overdosing. By formulating precise dosages, this study aims to make treatments safer and more effective for young patients. Another important aspect of this research is improving the medication's palatability. Children often find it difficult to swallow bitter or unappealing medicines, which can lead to poor adherence to their treatment regimen. Creating a formulation with improved taste and texture makes it more likely that children will take their medication consistently, leading to better treatment outcomes.

This paper explores the balance between drug effectiveness, safety, and patient comfort in paediatric TB treatments. By achieving this balance, the study hopes to contribute to higher recovery rates among young TB patients and reduce the risk of drug resistance that can occur when treatments are not properly followed. Ultimately, this work aims to support a healthier future for children affected by tuberculosis through a well-rounded and child-friendly treatment approach.

The second objective of this study is to examine the pharmacokinetics (how the drug moves through the body) and pharmacodynamics (how the drug affects the body) of newly formulated paediatric anti-tubercular medications. Understanding these aspects is crucial to ensuring that the drug reaches the optimal concentration in the body to fight tuberculosis effectively. The goal is to make sure that the drugs work well at different doses for children, ensuring they are absorbed properly, stay in the system long enough to be effective, and do not cause harmful effects. By studying pharmacokinetics and pharmacodynamics, the researchers aim to fine-tune the dosing to achieve the best therapeutic outcomes for paediatric patients.

The third objective focuses on evaluating the safety and tolerability of these new paediatric-specific medications through clinical trials. In these trials, researchers monitor how the medications affect children, checking for any potential side effects such as nausea, fatigue, or allergic reactions. They aim to identify any risks early and implement strategies to manage these side effects effectively. The goal is to ensure that the new medications are not only effective but also safe for children to use, reducing the chances of adverse

effects that could impact their health or quality of life. By achieving these three objectives, this study seeks to improve tuberculosis treatment for children, ensuring that the immediate-release formulations are both effective and safe, providing the best care for young patients with tuberculosis.

This table summarises the important points from the discussion on the efficacy and safety of immediate-release anti-tubercular formulations in paediatric tuberculosis treatment:

Main Aspects	**Findings**
Efficacy	Immediate-release anti-tubercular formulations are effective in reducing TB symptoms and promoting faster recovery in children.
Speed of Action	These formulations act quickly, providing the required drug concentration to combat the TB bacteria.
Safety	Generally safe when prescribed at recommended dosages.
Side Effects	Mild side effects such as gastrointestinal issues and skin rashes were observed but were manageable.
Overall Treatment Impact	Positive therapeutic outcomes were observed in paediatric TB treatment, with significant symptom reduction.
Monitoring Requirements	Close monitoring is needed to manage side effects and ensure proper treatment response.
Long-Term Considerations	Continued research is needed for further optimization of safety and efficacy, and for monitoring long-term effects.

Conclusion:

In this study, we evaluated the efficacy and safety of immediate-release anti-tubercular formulations for treating paediatric tuberculosis. The primary objective was to understand how well these medications work in children and to assess their safety profiles. Tuberculosis (TB) remains a significant health challenge, especially in children, and using the right medications is crucial for effective treatment. The findings highlight that immediate-release anti-tubercular formulations are effective in treating paediatric tuberculosis when used properly. These drugs work quickly in the body, providing the necessary concentration of the medication to fight the bacteria causing TB. The study showed that children who received these formulations showed a significant reduction in symptoms and faster recovery compared to those on other forms of TB treatment. This supports the use of immediate-release formulations as a reliable option in treating paediatric TB cases.

On the safety front, the study also found that immediate-release anti-tubercular medications are generally safe for children when prescribed according to the recommended dosages. However, like all medications, they can cause side effects, such as mild gastrointestinal disturbances and skin rashes. These side effects were typically manageable and did not significantly impact the overall treatment process. The results suggest that healthcare providers should be mindful of these potential side effects and monitor children closely during treatment. Overall, the study reinforces the importance of using effective and safe treatments for paediatric tuberculosis. Immediate-release anti-tubercular formulations have proven to be both effective in managing TB and relatively safe for use in children, offering a practical solution for healthcare providers.

However, continued monitoring and follow-up are essential to ensure the optimal outcomes for young patients. Moving forward, further research and clinical trials could provide deeper insights into how these medications can be improved for even better safety and efficacy in paediatric care.

References:

Athulnadh, B., Sreejith, K., Thasneem, K. M., Maniyan, N., Faris, P. M., & Neena, C. C. (2020). A review on paediatric adverse effects of first-line anti-tubercular drugs. *Journal of Drug Delivery and Therapeutics*, *10*(6), 216-218.

Hoagland, D., Zhao, Y., & E Lee, R. (2016). Advances in drug discovery and development for paediatric tuberculosis. *Mini reviews in medicinal chemistry*, *16*(6), 481-497.

Hussain, A., Singh, S., Das, S. S., Anjireddy, K., Karpagam, S., & Shakeel, F. (2019). Nanomedicines as drug delivery carriers of anti-tubercular drugs: from pathogenesis to infection control. *Current drug delivery*, *16*(5), 400-429.

Mane, S. S., Mandal, A., Pustake, M., Ali, M. K., & Yadav, N. (2022). Ocular Toxicity of Ethambutol During Both Intensive and Continuation Phases of Anti-Tubercular Therapy in Children. *Indian Paediatrics*, *59*(11), 863-866.

Matawo, N., Adeleke, O. A., & Wesley-Smith, J. (2020). Optimal design, characterization and preliminary safety evaluation of an edible orodispersible formulation for paediatric tuberculosis pharmacotherapy. *International Journal of Molecular Sciences*, *21*(16), 5714.

Motta, I., Calcagno, A., & Bonora, S. (2018). Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? *Expert opinion on drug metabolism & toxicology*, *14*(1), 59-82.

Mukherjee, A., Lodha, R., & Kabra, S. K. (2019). Pharmacokinetics of first-line anti-tubercular drugs. *The Indian Journal of Paediatrics*, *86*, 468-478.

Nandha, R., Garg, K., Singh, H., & Maheshwari, A. (2013). Bedaquiline: A Novel Addition to Anti-Tubercular Armamentarium. *Journal of Biomedical and Pharmaceutical Research*, *2*(2), 24-29.

Parumasivam, T., Chang, R. Y. K., Abdelghany, S., Ye, T. T., Britton, W. J., & Chan, H. K. (2016). Dry powder inhalable formulations for anti-tubercular therapy. *Advanced drug delivery reviews*, *102*, 83-101.

Tetali, S. R., Kunapaeddi, E., Mailavaram, R. P., Singh, V., Borah, P., Deb, P. K., ... & Tekade, R. K. (2020). Current advances in the clinical development of anti-tubercular agents. *Tuberculosis*, *125*, 101989.

Wang, L., Hong, Y., Wu, J., Leung, Y. K., & Huang, Y. (2017). Efficacy of thalidomide therapy in paediatric Crohn's disease with evidence of tuberculosis. *World journal of gastroenterology*, *23*(43), 7727.

Citation: **Nandi. A.,** (2024) "Optimizing Paediatric Tuberculosis Treatment: Efficacy and Safety of Immediate-Release Anti-Tubercular Formulations", *Bharati International Journal of Multidisciplinary Research & Development (BIJMRD)*, Vol-2, Issue-9, October-2024.